Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez
{"title":"[皮肤试验证明对辉瑞- biontech®疫苗过敏]。","authors":"Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez","doi":"10.29262/ram.v69i2.1088","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.</p><p><strong>Case report: </strong>30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.</p><p><strong>Conclusions: </strong>An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"69 2","pages":"89-92"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].\",\"authors\":\"Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez\",\"doi\":\"10.29262/ram.v69i2.1088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.</p><p><strong>Case report: </strong>30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.</p><p><strong>Conclusions: </strong>An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.</p>\",\"PeriodicalId\":21175,\"journal\":{\"name\":\"Revista alergia Mexico\",\"volume\":\"69 2\",\"pages\":\"89-92\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista alergia Mexico\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29262/ram.v69i2.1088\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v69i2.1088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].
Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.
Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.
Conclusions: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
